New 5-HT2A/5-HT2B/5-HT2C receptor agonists described by Beckley Psytech
Aug. 10, 2022
Beckley Psytech has divulged ergoline analogues acting as 5-HT2A and/or 5-HT2B and/or 5-HT2C receptor agonists reported to be useful for the treatment of depression.